Circulating tumor cells in newly diagnosed inflammatory breast cancer.

Breast Cancer Res 2015 Jan 9;17. Epub 2015 Jan 9.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Introduction: Circulating tumor cells (CTCs) are an independent prognostic factor for progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer. Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. The prognostic value of a CTC count in newly diagnosed IBC has not been established. The aim of this study was to assess the prognostic value of a baseline CTC count in patients with newly diagnosed IBC.

Methods: This retrospective study included 147 patients with newly diagnosed IBC (77 with locally advanced and 70 with metastatic IBC) treated with neoadjuvant therapy or first-line chemotherapy during the period from January 2004 through December 2012 at The University of Texas MD Anderson Cancer Center. CTCs were detected and enumerated by using the CellSearch system before patients were started with chemotherapy.

Results: The proportion of patients with ≥1 CTC was lower among patients with stage III than among patients with metastatic IBC (54.5% versus 84.3%; P=0.0002); the proportion of patients with ≥5 CTCs was also lower for stage III than for metastatic IBC (19.5% versus 47.1%; P=0.0004). Patients with fewer than five CTCs had significantly better progression-free survival (PFS) (hazard ratio (HR)=0.60; P=0.02) and overall survival (HR=0.59; P=0.03) than patients with five or more CTCs. Among patients with stage III IBC, there was a nonsignificant difference in PFS (HR=0.66; 95% confidence interval (CI), 0.31 to 1.39; P=0.29) and OS (HR=0.54; 95% CI, 0.24 to 1.26; P=0.48) in patients with no CTCs compared with patients with one or more CTCs. In multivariate analysis, CTC was prognostic for PFS and OS independent of clinical stage.

Conclusions: CTCs can be detected in a large proportion of patients with newly diagnosed IBC and are a strong predictor of worse prognosis in patients with newly diagnosed IBC.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-014-0507-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318180PMC
January 2015
21 Reads
8 Citations

Publication Analysis

Top Keywords

newly diagnosed
24
diagnosed ibc
16
breast cancer
16
patients newly
16
patients
15
proportion patients
12
patients ctcs
12
metastatic ibc
12
stage iii
12
ibc
9
patients stage
8
ctcs
8
ctc count
8
patients metastatic
8
survival pfs
8
progression-free survival
8
inflammatory breast
8
ctcs detected
8
circulating tumor
8
tumor cells
8

References

(Supplied by CrossRef)

NT Ueno et al.
Cancer Chemother Pharmacol 1997

H Masuda et al.
Ann Oncol 2014

TM Fouad et al.
Cancer Res 2013

M Cristofanilli et al.
Oncologist 2003

M Cristofanilli et al.
Cancer 2007

FM Robertson et al.
CA Cancer J Clin 2010

C Kleer et al.
Breast Cancer Res 2000

I Auwera Van der et al.
Clin Cancer Res 2004

M Parton et al.
Breast 2004

Similar Publications